Hellerstedt Beth A, Pienta Kenneth J
Division of Hematology/Oncology, University of Michigan Medical Center, 1150 West Medical Center Drive, Box 0640, 5301 MSRB III, Box 0640, Ann Arbor, MI 48109, USA.
Urol Oncol. 2003 Jul-Aug;21(4):272-81. doi: 10.1016/s1078-1439(03)00046-2.
Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.
雄激素剥夺疗法（ADT）是前列腺癌治疗的主要手段。ADT的理想时机、持续时间和组成仍不明确。目前，一线治疗包括睾丸切除术、促性腺激素释放激素（LHRH）激动剂或联合雄激素阻断（CAB）。然而，新的联合治疗方法和治疗方案有望改善治疗效果并降低毒性。
